Eli Lilly (LLY) traded down 0.68% at $1073.62 on January 13, 2026, following a positive analysis from Simply Wall St that emphasized strong share price momentum driven by its blockbuster weight-loss drug portfolio.
- Simply Wall St attributes the recent 33.07% 3-month return to projections that Mounjaro and Zepbound growth will surpass Novo Nordisk by 2026.
- The analysis suggests the stock is 9.1% undervalued, setting a fair value target of $1,189.18, despite noting a high P/E ratio of 52.6x.
- The minor decline aligns with broader market weakness, as the S&P 500 declined 0.24% and the Dow dropped 0.66% amid CPI data reactions.